While we have recently published the efficacy of pan-Wnt inhibition through Porcn inhibitors in Ewing sarcoma, here, we sought to focus on the heterogeneity of Wnt/β-Catenin activation in the tumor, and alternative methods to target the responsiveness of Ewing sarcoma cells to exogenous ligands. The gene discussed is PORCN; the disease is neoplasm.